Loading…
Protective effects of ginsenoside Rh1 on intervertebral disc degeneration through inhibition of nuclear factor kappa-B signaling pathway
Background: In this study, we aim to explore the protective effect of ginsenoside Rh1 against intervertebral disc degeneration (IDD) and the related mechanism. Materials and Methods: IDD model in Sprague-Dawley rats was established and the animals were treated with different concentrations of ginsen...
Saved in:
Published in: | Pharmacognosy Magazine 2021-01, Vol.17 (73), p.140-145 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c315i-e0be9aa1ad04fbae2539f440a6fb73ee9eb4d8f07990da3499d247e3f1941f703 |
---|---|
cites | cdi_FETCH-LOGICAL-c315i-e0be9aa1ad04fbae2539f440a6fb73ee9eb4d8f07990da3499d247e3f1941f703 |
container_end_page | 145 |
container_issue | 73 |
container_start_page | 140 |
container_title | Pharmacognosy Magazine |
container_volume | 17 |
creator | Zhang, Shuping Wang, Tong Wang, Xuexin Wang, Yanan Wang, Peng Li, Jinxia Wang, Zhenyu Lin, Faliang |
description | Background: In this study, we aim to explore the protective effect of ginsenoside Rh1 against intervertebral disc degeneration (IDD) and the related mechanism. Materials and Methods: IDD model in Sprague-Dawley rats was established and the animals were treated with different concentrations of ginsenoside Rh1 for 4 weeks, after this, the animals were sacrificed and the intervertebral disc of was collected for analysis using quantitative polymerase chain reaction. Western blot analysis was performed for quantifying the expression levels of glycosaminoglycans (GAGs) and Types I and Type II collagen. Moreover, serum samples were collected and the expression levels of some of the inflammatory cytokines such as interleukin (IL)-1 β and IL-6 were evaluated. Next, we collected the nucleus pulposus (NP) cells from the animals and were divided into five groups: control, IDD, treatment groups with different concentrations of ginsenoside Rh1 (10, 20, and 50 μg/mL). After treatment, the levels of IL-1 β and IL-6 in the cell culture supernatant were examined. Then, we performed western blot analysis to quantify the levels of B-cell lymphoma-2 (Bcl-2), B-cell lymphoma-extra-large (BCL-xL), and nuclear factor kappa-B (NF-κB) in different groups. Results: We observed that ginsenoside Rh1 significantly downregulated the expression of type I collagen and upregulated the expression of type II collagen and GAG under in vivo conditions. Moreover, the expression levels of IL-1 β and IL-6 in the serum samples of IDD rats and cell culture supernatant of NP cells isolated from the IDD rats were significantly increased. However, ginsenoside Rh1 significantly increased the levels of Bcl-2 and Bcl-xL and decreased the levels NF-κB both under in vitro and in vivo conditions. Conclusion: Ginsenoside Rh1 demonstrated protective effect against the IDD via regulation of IL-1 β/NF-κB signaling pathway. |
doi_str_mv | 10.4103/pm.pm_579_19 |
format | article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2532907975</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A658894980</galeid><sourcerecordid>A658894980</sourcerecordid><originalsourceid>FETCH-LOGICAL-c315i-e0be9aa1ad04fbae2539f440a6fb73ee9eb4d8f07990da3499d247e3f1941f703</originalsourceid><addsrcrecordid>eNptkV1rFTEQhhdRsFbv_AEBb91jssl-5EaopX5AQRG9DrObyW56dpM1yfbQf9CfbdpjFaHMxQzD875M8hbFa0Z3glH-bl1266LqViomnxQnVLZNKWhTPb2feckq2TwvXsR4RWndMdqeFLffgk84JHuNBI3JUyTekNG6iM5Hq5F8nxjxjliXMFxjSNgHmIm2cSAaR3QYINkMpCn4bZwyONne3q-yk9uGGSEQA0PygexhXaH8QKIdHczWjWSFNB3g5mXxzMAc8dWfflr8_Hjx4_xzefn105fzs8ty4Ky2JdIeJQADTYXpAauaSyMEhcb0LUeU2AvdGdpKSTVwIaWuRIvcMCmYaSk_Ld4cfdfgf20Yk7ryW8i3RJW9KpmVbf2PGmFGZZ3xKcCw5Ders6buOilkd-e1e4TKpXGxg3dobN7_J3h7FAzBxxjQqDXYBcKNYlTdRahyfn8jzPj7I37wc_78uJ-3Awa1oN47f3hUo5ig6iFT_htGfqfd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2532907975</pqid></control><display><type>article</type><title>Protective effects of ginsenoside Rh1 on intervertebral disc degeneration through inhibition of nuclear factor kappa-B signaling pathway</title><source>Publicly Available Content Database</source><source>Alma/SFX Local Collection</source><creator>Zhang, Shuping ; Wang, Tong ; Wang, Xuexin ; Wang, Yanan ; Wang, Peng ; Li, Jinxia ; Wang, Zhenyu ; Lin, Faliang</creator><creatorcontrib>Zhang, Shuping ; Wang, Tong ; Wang, Xuexin ; Wang, Yanan ; Wang, Peng ; Li, Jinxia ; Wang, Zhenyu ; Lin, Faliang</creatorcontrib><description>Background: In this study, we aim to explore the protective effect of ginsenoside Rh1 against intervertebral disc degeneration (IDD) and the related mechanism. Materials and Methods: IDD model in Sprague-Dawley rats was established and the animals were treated with different concentrations of ginsenoside Rh1 for 4 weeks, after this, the animals were sacrificed and the intervertebral disc of was collected for analysis using quantitative polymerase chain reaction. Western blot analysis was performed for quantifying the expression levels of glycosaminoglycans (GAGs) and Types I and Type II collagen. Moreover, serum samples were collected and the expression levels of some of the inflammatory cytokines such as interleukin (IL)-1 β and IL-6 were evaluated. Next, we collected the nucleus pulposus (NP) cells from the animals and were divided into five groups: control, IDD, treatment groups with different concentrations of ginsenoside Rh1 (10, 20, and 50 μg/mL). After treatment, the levels of IL-1 β and IL-6 in the cell culture supernatant were examined. Then, we performed western blot analysis to quantify the levels of B-cell lymphoma-2 (Bcl-2), B-cell lymphoma-extra-large (BCL-xL), and nuclear factor kappa-B (NF-κB) in different groups. Results: We observed that ginsenoside Rh1 significantly downregulated the expression of type I collagen and upregulated the expression of type II collagen and GAG under in vivo conditions. Moreover, the expression levels of IL-1 β and IL-6 in the serum samples of IDD rats and cell culture supernatant of NP cells isolated from the IDD rats were significantly increased. However, ginsenoside Rh1 significantly increased the levels of Bcl-2 and Bcl-xL and decreased the levels NF-κB both under in vitro and in vivo conditions. Conclusion: Ginsenoside Rh1 demonstrated protective effect against the IDD via regulation of IL-1 β/NF-κB signaling pathway.</description><identifier>ISSN: 0973-1296</identifier><identifier>EISSN: 0976-4062</identifier><identifier>DOI: 10.4103/pm.pm_579_19</identifier><language>eng</language><publisher>London: Wolters Kluwer India Pvt. Ltd</publisher><subject>Care and treatment ; Cell culture ; Cellular signal transduction ; Collagen ; Degenerative disc disease ; Ginseng ; Glycosides ; Health aspects ; Intervertebral disk ; Lymphoma ; Pharmacology, Experimental ; Spinal diseases ; Transcription factors</subject><ispartof>Pharmacognosy Magazine, 2021-01, Vol.17 (73), p.140-145</ispartof><rights>COPYRIGHT 2021 Medknow Publications and Media Pvt. Ltd.</rights><rights>2021. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c315i-e0be9aa1ad04fbae2539f440a6fb73ee9eb4d8f07990da3499d247e3f1941f703</citedby><cites>FETCH-LOGICAL-c315i-e0be9aa1ad04fbae2539f440a6fb73ee9eb4d8f07990da3499d247e3f1941f703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2532907975?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,4024,25753,27923,27924,27925,37012,44590</link.rule.ids></links><search><creatorcontrib>Zhang, Shuping</creatorcontrib><creatorcontrib>Wang, Tong</creatorcontrib><creatorcontrib>Wang, Xuexin</creatorcontrib><creatorcontrib>Wang, Yanan</creatorcontrib><creatorcontrib>Wang, Peng</creatorcontrib><creatorcontrib>Li, Jinxia</creatorcontrib><creatorcontrib>Wang, Zhenyu</creatorcontrib><creatorcontrib>Lin, Faliang</creatorcontrib><title>Protective effects of ginsenoside Rh1 on intervertebral disc degeneration through inhibition of nuclear factor kappa-B signaling pathway</title><title>Pharmacognosy Magazine</title><description>Background: In this study, we aim to explore the protective effect of ginsenoside Rh1 against intervertebral disc degeneration (IDD) and the related mechanism. Materials and Methods: IDD model in Sprague-Dawley rats was established and the animals were treated with different concentrations of ginsenoside Rh1 for 4 weeks, after this, the animals were sacrificed and the intervertebral disc of was collected for analysis using quantitative polymerase chain reaction. Western blot analysis was performed for quantifying the expression levels of glycosaminoglycans (GAGs) and Types I and Type II collagen. Moreover, serum samples were collected and the expression levels of some of the inflammatory cytokines such as interleukin (IL)-1 β and IL-6 were evaluated. Next, we collected the nucleus pulposus (NP) cells from the animals and were divided into five groups: control, IDD, treatment groups with different concentrations of ginsenoside Rh1 (10, 20, and 50 μg/mL). After treatment, the levels of IL-1 β and IL-6 in the cell culture supernatant were examined. Then, we performed western blot analysis to quantify the levels of B-cell lymphoma-2 (Bcl-2), B-cell lymphoma-extra-large (BCL-xL), and nuclear factor kappa-B (NF-κB) in different groups. Results: We observed that ginsenoside Rh1 significantly downregulated the expression of type I collagen and upregulated the expression of type II collagen and GAG under in vivo conditions. Moreover, the expression levels of IL-1 β and IL-6 in the serum samples of IDD rats and cell culture supernatant of NP cells isolated from the IDD rats were significantly increased. However, ginsenoside Rh1 significantly increased the levels of Bcl-2 and Bcl-xL and decreased the levels NF-κB both under in vitro and in vivo conditions. Conclusion: Ginsenoside Rh1 demonstrated protective effect against the IDD via regulation of IL-1 β/NF-κB signaling pathway.</description><subject>Care and treatment</subject><subject>Cell culture</subject><subject>Cellular signal transduction</subject><subject>Collagen</subject><subject>Degenerative disc disease</subject><subject>Ginseng</subject><subject>Glycosides</subject><subject>Health aspects</subject><subject>Intervertebral disk</subject><subject>Lymphoma</subject><subject>Pharmacology, Experimental</subject><subject>Spinal diseases</subject><subject>Transcription factors</subject><issn>0973-1296</issn><issn>0976-4062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkV1rFTEQhhdRsFbv_AEBb91jssl-5EaopX5AQRG9DrObyW56dpM1yfbQf9CfbdpjFaHMxQzD875M8hbFa0Z3glH-bl1266LqViomnxQnVLZNKWhTPb2feckq2TwvXsR4RWndMdqeFLffgk84JHuNBI3JUyTekNG6iM5Hq5F8nxjxjliXMFxjSNgHmIm2cSAaR3QYINkMpCn4bZwyONne3q-yk9uGGSEQA0PygexhXaH8QKIdHczWjWSFNB3g5mXxzMAc8dWfflr8_Hjx4_xzefn105fzs8ty4Ky2JdIeJQADTYXpAauaSyMEhcb0LUeU2AvdGdpKSTVwIaWuRIvcMCmYaSk_Ld4cfdfgf20Yk7ryW8i3RJW9KpmVbf2PGmFGZZ3xKcCw5Ders6buOilkd-e1e4TKpXGxg3dobN7_J3h7FAzBxxjQqDXYBcKNYlTdRahyfn8jzPj7I37wc_78uJ-3Awa1oN47f3hUo5ig6iFT_htGfqfd</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Zhang, Shuping</creator><creator>Wang, Tong</creator><creator>Wang, Xuexin</creator><creator>Wang, Yanan</creator><creator>Wang, Peng</creator><creator>Li, Jinxia</creator><creator>Wang, Zhenyu</creator><creator>Lin, Faliang</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Sage Publications Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20210101</creationdate><title>Protective effects of ginsenoside Rh1 on intervertebral disc degeneration through inhibition of nuclear factor kappa-B signaling pathway</title><author>Zhang, Shuping ; Wang, Tong ; Wang, Xuexin ; Wang, Yanan ; Wang, Peng ; Li, Jinxia ; Wang, Zhenyu ; Lin, Faliang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c315i-e0be9aa1ad04fbae2539f440a6fb73ee9eb4d8f07990da3499d247e3f1941f703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Care and treatment</topic><topic>Cell culture</topic><topic>Cellular signal transduction</topic><topic>Collagen</topic><topic>Degenerative disc disease</topic><topic>Ginseng</topic><topic>Glycosides</topic><topic>Health aspects</topic><topic>Intervertebral disk</topic><topic>Lymphoma</topic><topic>Pharmacology, Experimental</topic><topic>Spinal diseases</topic><topic>Transcription factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Shuping</creatorcontrib><creatorcontrib>Wang, Tong</creatorcontrib><creatorcontrib>Wang, Xuexin</creatorcontrib><creatorcontrib>Wang, Yanan</creatorcontrib><creatorcontrib>Wang, Peng</creatorcontrib><creatorcontrib>Li, Jinxia</creatorcontrib><creatorcontrib>Wang, Zhenyu</creatorcontrib><creatorcontrib>Lin, Faliang</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Pharmacognosy Magazine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Shuping</au><au>Wang, Tong</au><au>Wang, Xuexin</au><au>Wang, Yanan</au><au>Wang, Peng</au><au>Li, Jinxia</au><au>Wang, Zhenyu</au><au>Lin, Faliang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protective effects of ginsenoside Rh1 on intervertebral disc degeneration through inhibition of nuclear factor kappa-B signaling pathway</atitle><jtitle>Pharmacognosy Magazine</jtitle><date>2021-01-01</date><risdate>2021</risdate><volume>17</volume><issue>73</issue><spage>140</spage><epage>145</epage><pages>140-145</pages><issn>0973-1296</issn><eissn>0976-4062</eissn><abstract>Background: In this study, we aim to explore the protective effect of ginsenoside Rh1 against intervertebral disc degeneration (IDD) and the related mechanism. Materials and Methods: IDD model in Sprague-Dawley rats was established and the animals were treated with different concentrations of ginsenoside Rh1 for 4 weeks, after this, the animals were sacrificed and the intervertebral disc of was collected for analysis using quantitative polymerase chain reaction. Western blot analysis was performed for quantifying the expression levels of glycosaminoglycans (GAGs) and Types I and Type II collagen. Moreover, serum samples were collected and the expression levels of some of the inflammatory cytokines such as interleukin (IL)-1 β and IL-6 were evaluated. Next, we collected the nucleus pulposus (NP) cells from the animals and were divided into five groups: control, IDD, treatment groups with different concentrations of ginsenoside Rh1 (10, 20, and 50 μg/mL). After treatment, the levels of IL-1 β and IL-6 in the cell culture supernatant were examined. Then, we performed western blot analysis to quantify the levels of B-cell lymphoma-2 (Bcl-2), B-cell lymphoma-extra-large (BCL-xL), and nuclear factor kappa-B (NF-κB) in different groups. Results: We observed that ginsenoside Rh1 significantly downregulated the expression of type I collagen and upregulated the expression of type II collagen and GAG under in vivo conditions. Moreover, the expression levels of IL-1 β and IL-6 in the serum samples of IDD rats and cell culture supernatant of NP cells isolated from the IDD rats were significantly increased. However, ginsenoside Rh1 significantly increased the levels of Bcl-2 and Bcl-xL and decreased the levels NF-κB both under in vitro and in vivo conditions. Conclusion: Ginsenoside Rh1 demonstrated protective effect against the IDD via regulation of IL-1 β/NF-κB signaling pathway.</abstract><cop>London</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><doi>10.4103/pm.pm_579_19</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0973-1296 |
ispartof | Pharmacognosy Magazine, 2021-01, Vol.17 (73), p.140-145 |
issn | 0973-1296 0976-4062 |
language | eng |
recordid | cdi_proquest_journals_2532907975 |
source | Publicly Available Content Database; Alma/SFX Local Collection |
subjects | Care and treatment Cell culture Cellular signal transduction Collagen Degenerative disc disease Ginseng Glycosides Health aspects Intervertebral disk Lymphoma Pharmacology, Experimental Spinal diseases Transcription factors |
title | Protective effects of ginsenoside Rh1 on intervertebral disc degeneration through inhibition of nuclear factor kappa-B signaling pathway |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A12%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protective%20effects%20of%20ginsenoside%20Rh1%20on%20intervertebral%20disc%20degeneration%20through%20inhibition%20of%20nuclear%20factor%20kappa-B%20signaling%20pathway&rft.jtitle=Pharmacognosy%20Magazine&rft.au=Zhang,%20Shuping&rft.date=2021-01-01&rft.volume=17&rft.issue=73&rft.spage=140&rft.epage=145&rft.pages=140-145&rft.issn=0973-1296&rft.eissn=0976-4062&rft_id=info:doi/10.4103/pm.pm_579_19&rft_dat=%3Cgale_proqu%3EA658894980%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c315i-e0be9aa1ad04fbae2539f440a6fb73ee9eb4d8f07990da3499d247e3f1941f703%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2532907975&rft_id=info:pmid/&rft_galeid=A658894980&rfr_iscdi=true |